StockData
Standard BioTools Inc. logo

Standard BioTools Inc. (LAB) stock

LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3087% below fair value
$0.65+0.01 (+1.31%)

Close on Nov 12, 2026Market cap $255.73MP/E 3.0Yield –

Earnings

Standard BioTools's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 3, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$20.10M
-7.8% on a year earlier
Adjusted EPS, Q2 FY2026
–
Latest guidance
Issued
May 5, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Standard BioTools's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 30, 2026Nov 3, 2026Expected–––––
Q2 FY2026ended Jun 30, 2026Aug 5, 2026after the close$20.10M-7.8%––Release
Q1 FY2026ended Mar 31, 2026May 5, 2026after the close$21.10M-48.3%$0.33–Release
Q4 FY2025ended Dec 31, 2025Feb 24, 2026after the close$23.80M-49.0%$0.05–Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025after the close$46.20M+2.7%––Release
Q2 FY2025ended Jun 30, 2025Aug 11, 2025after the close$21.80M-41.4%––Release
Q1 FY2025ended Mar 31, 2025May 6, 2025after the close$40.80M–––Release
Q4 FY2024ended Dec 31, 2024Feb 26, 2025after the close$46.70M+65.7%-$0.09–Release
Q3 FY2024ended Sep 30, 2024Oct 30, 2024after the close$45.00M+77.2%-$0.07–Release
Q2 FY2024ended Jun 30, 2024Jul 31, 2024after the close$37.20M+34.3%-$0.12–Release
Q4 FY2023ended Dec 31, 2023Feb 28, 2024after the close$28.19M+4.4%-$0.25–Release
Q3 FY2023ended Sep 30, 2023Nov 7, 2023after the close$25.40M-0.8%-$0.27–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Standard BioTools's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenueFY2026$80.00M – $85.00M–NewMay 5, 2026
revenueFY2026$80.00M – $85.00M–NewFeb 24, 2026

Guidance vs results

The last range Standard BioTools gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$78.00M – $83.00M$132.60MΣ4QAbove range
Q4 FY2021Revenue$31.00M – $34.00M$38.30MAbove range

Guidance history

Every forecast Standard BioTools put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
May 5, 2026revenueFY2026$80.00M – $85.00MNew
Feb 24, 2026revenueFY2026$80.00M – $85.00MNew
Nov 4, 2025Revenue from continuing operationsFY2025$78.00M – $83.00MLowered
Nov 4, 2025combined revenueFY2025$165.00M – $175.00MNew
Aug 11, 2025Revenue from continuing operationsFY2025$78.00M – $83.00MLowered
Aug 11, 2025combined revenueFY2025$165.00M – $175.00MReaffirmed
May 6, 2025revenueFY2025$165.00M – $175.00MNew
Feb 26, 2025revenueFY2025$165.00M – $175.00MNew
Oct 30, 2024revenue guidanceFY2024$170.00M – $175.00MReaffirmed
Jul 31, 2024revenue guidanceFY2024$170.00M – $175.00MLowered
Feb 28, 2024revenueFY2024$200.00M – $205.00MNew
Nov 7, 2023GAAP gross marginFY202347%New
Nov 7, 2023non-GAAP gross marginFY202360%Lowered
Nov 7, 2023total revenueFY2023$100.00M – $105.00MNew
May 9, 2023Non-GAAP product and services marginsQ4 FY202365% – 68%Reaffirmed
May 9, 2023GAAP product and services marginsQ4 FY202352% – 55%Reaffirmed
May 9, 2023non-GAAP operating expensesFY2023$102.00M – $107.00MReaffirmed
May 9, 2023GAAP operating expensesFY2023$118.00M – $123.00MReaffirmed
Feb 14, 2023Non-GAAP product and services marginsQ4 FY202365% – 68%New
Feb 14, 2023GAAP product and services marginsQ4 FY202352% – 55%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Standard BioTools filed with the SEC as exhibits to Form 8-K or 6-K

  1. ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark Scientific
    Update
  2. Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
    Update
  3. Standard BioTools Provides Update on Sale of Mass Cytometry Business
    Update
  4. Standard BioTools Reports Second Quarter 2026 Financial Results
    Results
  5. Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
    Update
  6. Standard BioTools and Treeline Biosciences Announce
    Update
  7. Thank you for joining the Standard BioTools and Treeline Biosciences merger
    Update
  8. Transaction and Company Overview June 2026
    Update
  9. Standard BioTools Reports First Quarter 2026 Financial Results
    Results
  10. Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results
    Results
  11. Completes Sale of SomaLogic to Illumina
    Results
  12. Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
    Results
  13. Standard BioTools Reports Third Quarter 2025 Financial Results
    Results
  14. Standard BioTools Reports Second Quarter 2025 Financial Results
    Results
  15. Standard BioTools Enters Next Phase of Transformation
    Update

See a number that looks wrong?